{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T09:04:12Z","timestamp":1774343052064,"version":"3.50.1"},"reference-count":19,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:p>Guillain\u2010Barr\u00e9 Syndrome (GBS), an autoimmune neurological disease of peripheral nerves, has been causally associated with COVID\u201019 vaccination in adults. However, no such report has been published so far in children. We describe a 13\u2010year\u2010old female child who presented to the emergency department with complaints of bilateral upper limb, lower limb and truncal weakness over 3\u2009days following first dose of recombinant protein subunit COVID\u201019 vaccine (<jats:italic>Corbevax<\/jats:italic>). Clinical examination and nerve conduction studies showed pure motor axonal polyneuropathy with absent compound muscle action potential (CMAP) in all sampled nerves of upper and lower limbs which was consistent with the diagnosis of GBS after ruling out possible alternative aetiologies. A temporal association between first dose of protein subunit COVID\u201019 vaccine administered a day prior and symptom onset was noted. The causality assessment using the World Health Organization (WHO) tool for adverse event following immunization (AEFI) assessment indicated vaccine product\u2010related reaction categorized as A1. The patient's clinical condition improved after seven sessions of plasmapheresis. The purpose of this report is to create awareness among health care professionals about COVID\u201019 vaccine\u2010induced GBS in children as early diagnosis and management can be critical in avoiding complications and improving patient outcomes.<\/jats:p>","DOI":"10.1111\/bcp.15466","type":"journal-article","created":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T09:34:46Z","timestamp":1658309686000},"page":"556-560","source":"Crossref","is-referenced-by-count":8,"title":["Recombinant protein subunit COVID\u201019 vaccine\u2010induced Guillain\u2010Barr\u00e9 Syndrome in an adolescent: A case report"],"prefix":"10.1111","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7984-9351","authenticated-orcid":false,"given":"Rachna","family":"Rohilla","sequence":"first","affiliation":[{"name":"Department of Pharmacology Postgraduate Institute of Medical Education and Research  Chandigarh India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7768-7304","authenticated-orcid":false,"given":"Ashish Kumar","family":"Kakkar","sequence":"additional","affiliation":[{"name":"Department of Pharmacology Postgraduate Institute of Medical Education and Research  Chandigarh India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishna","family":"Divyashree","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Postgraduate Institute of Medical Education and Research  Chandigarh India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritin","family":"Mohindra","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Postgraduate Institute of Medical Education and Research  Chandigarh India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikas","family":"Suri","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Postgraduate Institute of Medical Education and Research  Chandigarh India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,8]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"World Health Organization.WHO coronavirus (COVID\u201019) dashboard.https:\/\/covid19.who.int\/. Accessed May 20 2022."},{"key":"e_1_2_10_3_1","unstructured":"https:\/\/www.mohfw.gov.in\/. Accessed May 23 2022."},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nerep.2022.100083"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr\u20102021\u2010242956"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26143"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.12691\/ajmcr-9-8-10"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr\u20102021\u2010243629"},{"key":"e_1_2_10_9_1","unstructured":"European Medicines Agency (EMA).COVID\u201019 Vaccine Janssen: Guillain\u2010Barr\u00e9 syndrome listed as a very rare side effect. 22 July2021.https:\/\/www.ema.europa.eu\/en\/news\/covid-19-vaccine-janssen-guillain-barre-syndrome-listed-very-rare-side-effect. Accessed July 27 2022."},{"key":"e_1_2_10_10_1","unstructured":"World Health Organization.Statement of the WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID\u201019 subcommittee on reports of Guillain\u2010Barr\u00e9 Syndrome (GBS) following adenovirus vector COVID\u201019 vaccines.https:\/\/www.who.int\/news\/item\/26-07-2021-statement-of-the-who-gacvs-covid-19-subcommittee-on-gbs. Accessed May 18 2022."},{"key":"e_1_2_10_11_1","unstructured":"https:\/\/cdsco.gov.in\/opencms\/opencms\/system\/modules\/CDSCO.WEB\/elements\/download_file_division.jsp?num_id=ODI0OAAccessed May 31 2022."},{"key":"e_1_2_10_12_1","unstructured":"Centers for Disease Control and Prevention.Selected adverse events reported after COVID\u201019 vaccination.https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/safety\/adverse-events.html#:~:text=Guillain%2DBarr%C3%A9%20Syndrome%20(GBS) ages%2050%20years%20and%20older. Accessed May 31 2022."},{"key":"e_1_2_10_13_1","volume-title":"Causality Assessment of an Adverse Event Following Immunization (AEFI): User Manual for the Revised WHO Classification","author":"World Health Organization"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.3399\/bjgp16X684733"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1006\/jaut.1999.0346"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy232"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2017.32.7.1154"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.13426"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.8879"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2021.106887"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15466","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.15466","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15466","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T08:45:42Z","timestamp":1692521142000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1111\/bcp.15466"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15466","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8]]}}}